31P-magnetic resonance spectroscopy (31P-MRS) detects early changes in kidney high-energy phosphate metabolism during a 6-month Valsartan treatment in diabetic and non-diabetic kidney-transplanted patients

被引：9

作者：

Fiorina, Paolo ^{[1
,2
,3
]}

Bassi, Roberto ^{[1
,3
]}

Gremizzi, Chiara ^{[2
]}

Vergani, Andrea ^{[1
]}

Caldara, Rossana ^{[2
]}

Mello, Alessandra ^{[4
]}

Del Maschio, Alessandro ^{[5
,6
]}

De Cobelli, Francesco ^{[5
]}

Perseghin, Gianluca ^{[7
]}

Secchi, Antonio ^{[2
,6
]}

机构：

[1] Harvard Univ, Brigham & Womens Hosp, Div Nephrol, Transplantat Res Ctr,Childrens Hosp,Med Sch, Boston, MA 02115 USA

[2] Ist Sci San Raffaele, Dept Med, I-20132 Milan, Italy

[3] Univ Salento, DiSTeBA, Lecce, Italy

[4] Ist Sci San Raffaele, Dept Anhestesiol, I-20132 Milan, Italy

[5] Ist Sci San Raffaele, Dept Radiol, I-20132 Milan, Italy

[6] Univ Vita Salute, Milan, Italy

[7] Fac Sci Motorie, Milan, Italy

来源：

ACTA DIABETOLOGICA | 2012年 / 49卷

关键词：

Kidney transplantation; Kidney spectroscopy; Angiotensin receptor antagonists; PANCREAS TRANSPLANTATION; RENAL-TRANSPLANTATION; UREMIC PATIENTS; HYPERTENSION; VIABILITY;

D O I：

10.1007/s00592-012-0369-2

中图分类号：

R5 [内科学];

学科分类号：

1002 ; 100201 ;

摘要：

P-31-magnetic resonance spectroscopy (P-31-MRS) is a non-invasive tool to study high-energy phosphate (HEP) metabolism. We evaluate whether P-31-MRS can detect early changes in kidney HEP metabolism during a 6-month trial with Valsartan. Twenty consecutive stable and normotensive kidney-transplanted patients were enrolled. Nine of them received short-term low-dose Valsartan treatment (80 mg/day) for 6 months, while 11 controls received no medication. Kidney HEP metabolism was evaluated both at baseline and after treatment by P-31-MRS with a 1.5 T system (Gyroscan Intera Master 1.5 MR System; Philips Medical Systems, Best, The Netherlands). Valsartan-treated patients (n = 9) showed a significant increase in beta-ATP/Pi ratio, a marker of kidney HEP metabolism (baseline = 1.03 +/- 0.08 vs. 6 months = 1.26 +/- 0.07, p = 0.03). In contrast, the beta-ATP/Pi ratio in the control group (n = 11) did not change (baseline = 0.85 +/- 0.10 vs. 6 months = 0.89 +/- 0.08, ns). The improvement in the beta-ATP/Pi ratio was not associated with a reduction in arterial blood pressure or in urinary albumin excretion. Kidney-localized P-31-MRS can detect early changes in kidney HEP metabolism during a short-term low-dose Valsartan treatment in stable normotensive kidney-transplanted patients.

引用

页码：S133 / S139

页数：7

共 22 条

[1] Efficacy and safety of valsartan, an angiotensin II receptor antagonist, in hypertension after renal transplantation:: A randomized multicenter study [J].